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KELAZIMAN KANSER MULUT DAN PENGLIBATAN FAKTOR-
FAKTOR RISIKO DAN STATUS HASIL RAWATAN KARSINOMA SEL 
SQUAMOUS ORAL DI KELANTAN : KAJIAN RETROSPEKTIF 
ABSTRAK  
Kanser adalah pertumbuhan sel yang tidak terkawal yang disebabkan 
ketidakseimbangan antara apoptosis dan pembahagian sel. Kanser oral adalah salah satu 
daripada kanser yang paling lazim di seluruh dunia dan menurut Pertubuhan Kesihatan 
Sedunia, pada tahun 2018, 199,560 daripada 665,093 pesakit kanser oral yang baru 
didiagnosis telah meninggal dunia. Kanser oral berpunca daripada mutasi DNA yang 
boleh menjejaskan pelbagai gen dan mempunyai etiologi pelbagai faktor, iatu merokok 
tembakau yang paling ketara, pengambilan alkohol, mengunyah sirih, kecenderungan 
genetik dan jangkitan HPV. Karsinoma sel squamous oral mewakili 90% daripada jumlah 
kanser mulut. Lidah dianggap sebagai lokasi intra-oral yang paling lazim terlibat dengan 
kanser mulut. Lelaki dan individu yang berumur (> 55 tahun) lebih cenderung mengalami 
kanser mulut. Di Malaysia, 327 daripada 667 pesakit kanser mulut yang baru didiagnosis 
meninggal dunia pada tahun 2018. Radiasi dan pembedahan adalah satu-satunya cara 
rawatan yang berkesan untuk karsinoma mulut. Kemoterapi sendiri bukan terapi 
pemulihan; Walau bagaimanapun, ia boleh meningkatkan hasil jika digunakan dalam 
kombinasi radiasi untuk kanser yang sudah merebak di lokasi berhampiran. Dalam kajian 
retrospektif ini (2000 - 2018), data mengenai faktor sosio-demografi, klinik-patologi dan 
hasil rawatan yang berkaitan dengan kanser mulut telah dikumpulkan dari arkib rekod 
perubatan Hospital Universiti Sains Malaysia. Daripada 301 pesakit kanser mulut, 
xix 
majoriti pesakit mempunyai karsinoma sel squamous oral (n = 211). Umur nilai purata 
adalah 55 tahun. Pesakit lelaki (n = 189, 62.79%) adalah lebih daripada pesakit wanita (n 
= 112, 37.21%). Majoriti daripada mereka adalah bukan perokok (n = 173, 57.47%), 
bukan peminum alkohol (n = 251, 83.38%) dan bukan pengunyah sirih (n = 291, 96.67% 
) Melayu (n = 207, 68.77%). Lokasi yang paling kerap terlibat dengan kanser mulut ialah 
lidah (n = 107). 86.71% pesakit menerima rawatan dan 208 daripada 301 pesakit 
terselamat, manakala 93 pesakit kanser mulut meninggal dunia. Penggunaan alkohol, 
pembentangan / diagnosis lewat, pengkelasan histologi yang tidak dibezakan dan kes yang 
tidak dirawat dikaitkan dengan peningkatan risiko kematian. Faktor lain termasuk umur, 
etnik, betel quid mengunyah, sejarah keluarga tumor lepas, faktor predisposisi HPV dan 
tapak tumor mempunyai persamaan yang tidak signifikan dengan kadar kematian OSCC. 
Kesimpulannya, faktor risiko berpotensi yang berkaitan dengan kanser mulut wujud di 










PREVALENCE OF ORAL CANCER AND ASSOCIATION OF RISK 
FACTORS WITH TREATMENT OUTCOME STATUS OF ORAL SQUAMOUS 
CELL CARCINOMA IN KELANTAN: A RETROSPECTIVE  
ABSTRACT 
Cancer is an unchecked growth of cells due to an imbalance between apoptosis 
and cell division. Oral cancer is one of the most prevalent cancers worldwide and 
according to the World Health Organization in 2018, 199,560 out of 665,093 newly 
diagnosed oral cancer patients died. Oral cancer results from mutations in the DNA 
that can affect different genes and has multifactorial etiology, most significantly 
tobacco smoking, alcohol intake, betel quid chewing, genetic predisposition and HPV 
infection. Oral squamous cell carcinoma (OSCC) represents 90% of the total oral 
cancers. Tongue is considered as the most commonly involved intra-oral site for oral 
cancers. Males and old individuals (> 55 years) are more likely to be encountered with 
oral cancers. In Malaysia, 327 out of 667 newly diagnosed oral cancer patients died in 
2018. Radiation and surgery are the only reliable methods of treatment for early and 
locally advanced carcinoma of the mouth. Chemotherapy alone is not a remedial 
therapy; however, it may improve results if used in combination with radiation for 
locally advanced diseases. In this retrospective study (2000 – 2018), data regarding 
socio-demographic, clinico-pathological factors and treatment outcome associated 
with oral cancer was gathered from the archives of medical records of Hospital 
Universiti Sains Malaysia. Out of 301 oral cancer patients, the majority of the patients 
had OSCC (n=211). The mean age was 55 years. Male patients (n=189, 62.79%) were 
xxi 
more than female patients (n=112, 37.21%). Majority of them were non-smoker 
(n=173, 57.47%), non-alcohol consumer (n=251, 83.38%) and non-betel quid chewer 
(n=291, 96.67%) Malay (n=207, 68.77%). The most commonly involved site by oral 
cancer was tongue (n=107). 86.71% patients received treatment and 208 out of 301 
patients survived, whereas 93 oral cancer patients died. Alcohol consumption, late 
presentation/diagnosis, poorly differentiated histological grading and untreated cases 
were associated with an increased risk of mortality. Other factors including age, 
ethnicity, betel quid chewing, past family history of tumor, HPV predisposing factors 
and tumor site had a non-significant association with the mortality rate of OSCC. In 












CHAPTER 1.  
INTRODUCTION 
1.1 Background of the study 
Quoted from the inaugural speech of Prof. Wilfried Schilli from the University of 
Freiburg, Germany, in 1989 (Das and Nagpal, 2002): 
‘According to the World Health Organization (WHO) agreement of 1973, oral 
cancer is a malignant neoplasm in the 8 anatomic regions of the oral cavity. Thus, oral 
cancer refers to cancerous tumours of the upper respiratory and alimentary tracts and in 
the near vicinity, whose draining lymphatic vessels are all located in the neck. Since the 
treatment of malignant disease which has spread to the lymphatic system entails treating 
the lymphatics and the primary tumour as one entity, the therapeutic plan must include the 
neck region. Thus, the definition of oral cancer also applies to so called neck and head 
tumors’. 
Oral cancer is one of the most prevalent cancers worldwide and it attributed as the 
leading cause of death in certain geographical regions such as South-Central Asia (Gupta 
et al., 2016). Oral squamous cell carcinoma (OSCC) represents 90% of the total oral 
cancers (Massano et al., 2006). Tongue is considered as the most commonly involved 
intra-oral site for oral cancers (Moore et al., 2000b). Posterior-lateral border and ventral 
surfaces of the tongue are the most frequently involved sites in tongue cancers followed 
by floor of the mouth. Relatively less common intra-oral sites are gingiva, hard palate, 
buccal and labial mucosa (Zini et al., 2010).  
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Sometimes, they are preceded by precancerous lesions including leukoplakia and 
erythroplakia (Neville and Day, 2002). Males and older individuals (> 55 years) are more 
likely to be encountered with oral cancers (Kanasi et al., 2016).   
Globally, approximately 300,000 new cases of oral cancers are diagnosed 
annually. Developing countries account for around 75% of all oral cancers (De Souza et 
al., 2016). There is a significant local variation regarding the incidence of oral cancers. In 
south east Asia, oral cancers account for almost half of all malignancies, having betel quid 
chewing and tobacco use as the major contributing factors. A hike in the prevalence of 
oral cancers among young adults has been a cause of special concern. Over the past 30 
years, the incidence of tongue cancers has increased up to 60% in adults who are aged 
under 40 years (Boffetta et al., 2008).  Variations have been recognized at molecular level 
and the clinic-pathological behavior in alcohol-associated and tobacco-smoking oral 
cancers in Japan, United States (US), France, United Kingdom as well as tobacco-chewing 
oral carcinomas in south east Asia (Paterson et al., 1996). In Malaysia, the Indian race was 
detected to have higher risk of oral cancers than Malays and Chinese (Zain, 2001).  
The habits of alcohol consumption, betel-quid chewing, and tobacco smoking are 
established cultural risk factors associated with pre-malignant oral lesions and oral cancers 
(Goldenberg et al., 2004).  In some regions of the world, variations are observed due to 
different types of ethnicities in a population. Such inter-ethnic differences might be due 
to genetic predisposition of various ethnicities towards an escalated risk of pre-malignant 
oral lesions and oral cancers (Zain, 2001).  
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Human papilloma virus (HPV) is known to be a risk factor for head and neck 
cancers. In the US, the percentage of HPV-associated OSCC has risen from 20% to more 
than 70% (Sathish et al., 2014). 
The successful treatment outcome of the oral cancers depends on the appropriate 
management of both the loco-regional lymphatics and the primary site. The site of the 
primary tumour occurrence, the tumour size (T stage), nodal metastasis (N stage) and 
extra-capsular spread of the primary tumour dictates the treatment modality – 
chemotherapy (CT), radiotherapy (RT), surgery or a combination (Sankaranarayanan et 
al., 2015).  
The site of oral cancer determines its prognosis. Loco-regional involvement of 
lymph nodes signifies the most vital prognostic factors. The five-year survival rate 
declines to 20% from 40% with the involvement of lymph nodes (Bagan et al., 2010). 
Development of second primary cancer, poorly differentiated and large sized tumours are 
associated with decreased survival rate. Hence, prevention and early detection of oral 
cancers remain crucial (Petersen, 2009; Rivera, 2015).  
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1.2 Justification of the study 
In Malaysia, oral cancer is the 19th most common cancer which cannot be 
considered among the top “killer” malignancies when compared with other cancers such 
as ovarian and breast cancers. However, the concerns related to its burden of death cannot 
be brushed aside. The studies of risk factors, treatment modalities and outcome of oral 
cancer are not only of research interest, but also of clinical importance. Head and neck 
surgery alone or in combination with radiotherapy and chemotherapy procedures are 
performed to achieve good results. More importantly, in order to offer better awareness, 
prevention and treatment options, it is better for the people to avoid the associated risk 
factors. So, this study will be beneficial for awareness of people about the associated risk 
factors and treatment outcomes of the oral cancers, eventually for prevention of cancers. 
Therefore, it is imperative to determine the prevalence of oral cancers and associated risk 
factors which influence treatment outcome status of patients suffering from oral cancer. 
1.3 Objectives of the study 
1.3.1 General objective 
To determine the prevalence and association of risk factors with treatment 
outcome status of oral cancer in patients who attended Hospital Universiti Sains Malaysia 
from January 2000 to December 2018.  
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1.3.2 Specific Objective 
i. To determine the prevalence and association of socio-demographic as well as clinico-
pathological risk factors with oral cancer. 
ii. To determine the prevalence and association of socio-demographic as well as clinico-
pathological risk factors with oral squamous cell carcinoma. 
iii. To determine the association of socio-demographic and clinico-pathological factors 
with treatment outcome status of oral squamous cell carcinoma. 
1.4 Research questions 
i. What is the prevalence and association of risk factors with treatment outcome status 
of oral cancer patients who attended Hospital Universiti Sains Malaysia from January 
2000 to December 2018? 
1.5 Null hypothesis 
i. Age, gender, ethnicity, betel quid chewing and genetic predisposition are not the risk 
factors associated with development of oral cancer in Kelantanese population.  
ii. Tobacco smoking, alcohol drinking, and human papilloma virus infection are 
associated with development of oral cancer in Kelantanese population. 
iii. Tumor site, histological grading, TNM classification and TNM grading of tumor as 
well as treatment status are associated with the mortality rates of oral cancer in 
Kelantanese population. 
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CHAPTER 2.  
LITERATURE REVIEW 
2.1 Cancer  
Cancer is an unchecked growth of cells due to an imbalance between apoptosis 
and cell division (Ponder, 2001). According to WHO (World Health Organization, 2009), 
cancer is a disease caused by inherited and somatic mutations in genes known as tumour 
suppressor genes (TSG) and oncogenes.  
Under normal circumstances, old and damaged cells are replaced by new cells. 
However, during cancer, the cell’s DNA is damaged or altered causing mutations, thus 
influencing growth of cell. A tumour can be categorized either as malignant or benign. A 
malignant tumour has the ability to spread to nearby tissues (local invasion) as well as 
other parts of the body (metastasis). A benign tumour is localized and does not spread to 
other parts of the body (Lichtenstein, 2005).  
According to the American National Cancer Institute (National Cancer Institute, 
2009), cancer can be classified into five primary types including central nervous system 
cancers, sarcomas, leukaemias, carcinomas, myelomas and lymphomas. Cancers of 
central nervous system arise from tissues of spinal cord and brain. Sarcomas arise from 
the supportive tissues which constitute bone, cartilage, blood vessels, fat, connective 
tissues and muscle. Leukaemia is an immature blood cells’ cancer that arises from the 
bone marrow and has the possibility to accumulate in abundant quantity in the 
bloodstream. Carcinoma is the most common type of cancer that arises from the cells that 
cover external (Sen et al.) and internal surfaces, i.e. mouth, lung, breast and colon. 
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Myeloma and lymphoma arise from cells and lymph nodes present in the human immune 
systems. Table 1 shows a brief history of oral cancer through the ages.  
Table 2.1 Oral cancer through the ages timeline (Petrosyan et al., 2019) 
Year Significant discovery 
3000 BC First recorded description of cancer (breast cancer) 
1550 BC Oral cancer described 
460 BC Terms ‘carcinoma’ and ‘cancer’ created by Hippocrates 
30 AD A. Celsus surgically excised cancer of face and lip 
200 Humoral theory of cancer aetiology popularised by Galen 
1215 Surgery prohibited by the Catholic Church 
1478 First printed edition of A. Celsus’ ‘De Medicina’ in Florence, 
Italy 
1653 Lymphatic system discovered 
1664 First glossectomy performed by P. Marchetti 
1740 First cancer hospital in Rheims, France 
1761 Tobacco snuff causes cancer 
1858 R. Virchow published ‘Die Cellularpathologie’ 
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1885 H. T. Butlin’s ‘Diseases of the tongue’ F. Jawdyński performed 
first neck dissection for a metastatic tongue cancer 
1888 F. Jawdyński performed first neck dissection for a metastatic 
tongue cancer 
1891 W. Halstead advised radical resection en – bloc lymphatics in 
breast cancer cases 
1895 X-rays discovered by Roentgen 
1898 The Curies discovered Radium 
1902 Polya and von Navratil describe lymphatic drainage from oral 
anatomical sites 
1906 G. W. Crile’s landmark neck dissection paper 
1951 1450 cases of radical neck dissections by the Hayes Martin group 
1962 O. Suarez describes the functional neck dissection 
1965 V. Y. Bakamjian repopularises the deltopectoral flap 
1979 S. Ariyan introduced the pedicled pectoralis major myocutaneous 
flap 
1981 G.F Yang published success with radial forearm free flap 
9 
1989 D. Hidalgo reconstructs 10 mandibular defects with fibula free 
flaps 
1991 Committee for Head and Neck Surgery and Oncology of the 
American Academy of Otolaryngology - Head and Neck Surgery 
(AAO-HNS) standardised neck dissection 
2002 Update on neck dissection terminology by the American Head 
and Neck Society 
2017 Sentinel node biopsy supported by National Institute for Health 
and Care Excellence (NICE) 
2.2 Hallmarks of cancer 
Over the past 30 years, hundreds of cancer-associated genes have been identified. 
Some, for instance TP53, are commonly mutated; others, including ABL, are only mutated 
in certain leukemias. Each cancer gene has a defined function whose dysregulation 
contributes to the initiation or progression of malignancy. Therefore, it is better to consider 
cancer-related genes in the context of several fundamental alterations in cell physiology, 
the so-called distinctive signs of cancer, i.e. hallmarks of cancer, which collectively dictate 
the malignant phenotype (Hanahan and Weinberg, 2011): 
 
iv. Evading growth suppressors 
v. Avoiding immune destruction 
vi. Enabling replicative immortality 
vii. Tumour promoting inflammation 
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viii. Activating invasion and metastasis  
ix. Inducing angiogenesis  
x. Genome instability and mutation 
xi. Resisting cell death  
xii. Deregulating cellular energetics  
xiii. Sustaining proliferative signaling 
 
 
Figure 2.1 Hallmarks of cancer (Hanahan and Weinberg, 2011). 
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2.3 Cancer and cell cycle 
Every cell is programmed to multiply and die. This ordered but complex program 
is controlled by the centre of the cell “nucleus” which contains chromosomes containing 
many genes made up of DNA (Kastan and Bartek, 2004). Sometimes, some of these genes 
undergo a change. The nucleus then sends out abnormal orders and the cell goes wrong. 
It multiplies uncontrollably and takes on a life of its own. Each new cell produced contains 
the same defect. The cells proliferate chaotically and form a tumour (Evan and Vousden, 
2001). This process may be short, but is often long. 10-30 years may separate the birth of 
a first abnormal cell from the appearance of a tumour of about 1cm3 (Massagué, 2004). 
Cancer was considered to initiate when the rate at which cells grow exceeds the 
rate at which cells die, so that cells divide at an uncontrollable speed (Foster, 2008). Now, 
it is accepted that cancer is described more accurately as the product of a defect within the 
regulation of the cell cycle, so that wounded or mutated cells that normally die can 
progress through the cell cycle, acquiring mutations (Saiki et al., 2017). Mutations mostly 




Figure 2.2 Genes affecting cell cycle control (with acknowledgement to Scully C, 
Warnakulasuriya S. Cancer of the mouth for the dental team. Comprehending the 
condition, causes, controversies, control and consequences (Kalavrezos, 2015). 
 
 
One of the main proteins that regulate on a very high level is p53 (nicknamed as 
the “Guardian of the Genome”) (Efeyan and Serrano, 2007). It is so important, actually, 
that Science magazine called it the “molecule of the year” in 1993 (Culotta and Koshland 
Jr, 1993). p53 will bind DNA directly to produce proteins that block the progression of 
the cell cycle (Chen, 2016a). One of those proteins include p21. p21 will function to inhibit 
cyclin-dependent kinase (CDK). So, the CDK will not be able to activate DNA replication 
or activate mitosis (Karimian et al., 2016). Retinoblastoma (RB) is another protein that is 
associated with the function of p53 and these proteins are considered as TSGs, so RB is a 
protein that is produced from a TSG, just like p53 (Giacinti and Giordano, 2006). If they 
are defected, or if they have a mutation in them that causes loss of function, cancer arises. 
More than 50% of tumours have a defect in p53. RB got its name because a defect in RB 
would lead to a tumour of the eye known as retinoblastoma, which is why these two genes 
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are considered as TSGs (Golabchi et al., 2018). p21 is very unusual in that it does not 
actually lead to cancer when it is defected. Instead, it has been reported that mice that are 
without p21 have the ability to regenerate their limbs (Arthur and Heber-Katz, 2011).  
2.4 The Hayflick limit 
In 1961, Leonard Hayflick and his colleague Paul Moorhead discovered that 
normal cultured human cells have limited ability of division, after which they cease to 
grow, start to enlarge, engaging in new mechanism that has been called replicative 
senescence (Hayflick and Moorhead, 1961). At that time, it was totally unexpected 
because the research community strictly believed that such cells were immortal. In order 
to support the idea that normal human cells are mortal, Hayflick and Moorhead 
simultaneously cultured separate populations of male and female human fibroblasts. 
Today, it is known that this withdrawal from the cell cycle after a definite number of cell 
divisions (replicative senescence) is triggered because of shortened telomeres 




Figure 2.3 All somatic normal human cells display progressive telomere shortening 
with increased cell divisions. In the absence of a mechanism to maintain telomeres, cells 
eventually undergo replicative senescence (aging). Ectopically expressing just, the 
catalytic subunit telomerase reverse transcriptase (TERT) of the telomerase holoenzyme 
complex is sufficient to maintain telomere length and immortalize normal cells. 
Although normal cells with or without telomerase activity are not transformed, in the 
background of additional oncogenic changes, normal cells not only upregulate or 
reactivate telomerase but can become fully malignant (Shay and Wright, 2011). 
2.5 Telomeres and telomerase  
Telomerase is a ribonucleoprotein enzyme which was first discovered in 
Tetrahymena (Greider and Blackburn, 1985). Recently, telomerase has been identified in 
a line of immortal human cancer cells (Shay and Wright, 2019). The mechanism of action 
of telomerase is a repetitive duplication of the template domain, which involves an 
elongation phase during which the deoxyribonucleotides are added in sequence to the 3 
'end of the telomere, ensued by a slower "translocation" phase, during which the relative 
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position of telomerase and telomere advances one repetition, hence positioning the 
enzyme for another elongation phase (Leão et al., 2018). 
Cancer cells have developed the ability to overcome senescence via mechanisms 
that can maintain telomere length (for instance telomerase expression), which allows 
tumour cells to grow indefinitely, a biomarker of almost every human malignancy (Lasry 
and Ben-Neriah, 2015). Telomerase, which is detected in approximately 90% of all 
malignant tumours (Shay, 2016), might predict poor or favourable outcome (Wu et al., 
2016), which makes telomerase a very attractive biomarker and a target for making 
mechanism-based cancer diagnostics, therapeutics and prognostics (Platella et al., 2017). 
 
 
Figure 2.4 With increasing cell divisions, telomeres progressively shorten. Even in 
stem cells that self-renew, there is a gradual shortening of telomeres. After a finite 
number of cell doublings, eventually the cells have sufficient short telomeres that they 
undergo a growth arrest called senescence or the mortality stage 1 (M1). This has also 
been termed the Hayflick limit. Premalignant cells that have obtained a number of 
oncogenic changes can bypass M1 and enter into an extended lifespan period. This has 
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been termed the extended lifespan period, but eventually these cells also slowdown in 
proliferation and enter a period called crisis. In crisis, there is a balance between cell 
growth and apoptosis, and the vast majority of the cell population dies. A rare cell can 
upregulate telomerase or the much rarer alternative lengthening of telomerase (ALT) 
pathway and continue to proliferate. The hallmark of cells escaping crisis is, almost 
universally, stable but short telomere lengths and telomerase activity (Shay, 2016). 
 
2.6 Molecular events in oral carcinogenesis  
Carcinogenesis is a multi-stage process of aggregation of gene defects that are 
responsible for determining the characteristic traits of the cancer (Lichtenstein, 2005). It 
includes initiation, promotion, progression and malignant transformation (Tomasetti and 
Vogelstein, 2015). The development of cancer requires multiple genetic alterations 
affected by genetic predisposition and vulnerability to environmental carcinogens such as 
tobacco smoking, alcohol consumption, viral infection and chronic inflammation  




Figure 2.5 Clinical and Molecular Progression of Oral Cancer. (A) A typical clinical 
presentation of oral cancer. Benign squamous hyperplasia can often appear similar to 
normal mucosa. Novel molecular approaches have yielded considerable understanding 
of the field-cancerization hypothesis. (B) Normal-appearing mucosa already harbours 
early genetic changes (Farah et al., 2014). 
 
2.6.1 Oncogenes and proto-oncogenes 
Genes whose protein products are considered important for signalling normal cell 
growth and whose mutation or overexpression lead to uncontrolled cell growth and to 
tumorigenesis are termed as "oncogenes" (Pierotti et al., 2016). The first oncogenes were 
identified through the study of retroviruses (Mahalingam et al., 2002). Based on the 
biochemical and functional properties of protein products of proto-oncogenes (normal 
counter parts of oncogenes), oncogenes can be categorized in to five groups. These are 
(Bateman et al.) growth factors, (2) growth factor receptors, (Benowitz et al.) transcription 
factors, (4) signal transducers, and (5) others, such as apoptosis regulators (Pierotti et al., 
2016).  
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Epidermal growth factor receptor (EGFR) and its ligands have been extensively 
studied in OSCC (Jia et al., 2016; Kakei et al., 2017; Liu et al., 2019; Minabe et al., 2019; 
Zeng et al., 2000). Transforming growth factor (TGF-α) mRNA was found at levels 5 
times higher in 95% of histologically normal tissues of OSCC patients and at levels 5 
times higher in 88% of tumours than in normal mucosa (Das and Nagpal, 2002). EGFR 
mRNA increased 28 times in 92% of histologically normal tissues in cancer patients and 
increased 70 times in 91% of tumours than in normal mucosa (Grandis and Tweardy, 
1993). Overexpression and amplification of c-myc/N-myc have been detected in 20-40% 
of oral cancers (Alrani et al., 2016; Saranath et al., 1989; Sharma et al., 2017). The 
amplification of K-ras / N-ras, a point mutation in H-ras and the loss of the H-ras allele 
have been associated with oral cancer induced by tobacco chewing (Hoeben et al., 2016; 
Krishna et al., 2015; Prasad et al., 2018; Saranath et al., 1991; Xu et al., 1998).  
Several studies in western countries have also demonstrated an amplification of 
11q13, which contains the oncogenes int-2, hst-1, cyclin D1 (prad-1 / bcl-1), in 30-50% 
of OSCC patients (Barros-Filho et al., 2018; Blessmann et al., 2013; Huang et al., 2006; 
Huang et al., 2002; Izzo et al., 1998; Noorlag et al., 2015; Ramos-García et al., 2019; 
Ramos-García et al., 2017; Reshmi et al., 2007; Shuster et al., 2000; van Kempen et al., 
2015), and these amplifications are linked with poor prognosis (Meredith et al., 1995; 
Williams et al., 1993). Recently, it has also been proposed that constitutive activation of  
Signal transducer and activator of transcription 3 (Stat-3) is an early event in oral 
carcinogenesis (Alkharusi et al., 2019; Chen et al., 2019). 
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2.6.2 Tumor suppressor genes 
By acting as transducers of negative growth signals, TSGs are involved in 
regulation of cell cycle including cell cycle arrest and programmed cell death (apoptosis) 
(Marshall, 1991; Weinberg, 1991). The most vital TSG that is located on chromosome 
17p13.1 is the p53 gene (Ho and Lane, 2018). It has been named as "Guardian of the 
Genome", since having its important role in maintaining genome stability, cell cycle 
progression, DNA repair, cell differentiation, and apoptosis (Chen, 2016b). Several 
mechanisms, such as point mutations, deletion and binding to cellular and viral proteins, 
may lead to inactivation of p53 gene (Joerger and Fersht, 2016). Mutation of p53 gene in 
25-70% of oral cancers has been reported in several studies (Ali et al., 2017; Langdon and 
Partridge, 1992; Shah et al., 2011; Sinevici and O’sullivan, 2016; Yeh et al., 2003).  
In 20% of oral cancer (Patel et al., 2018) and 22% of oral leukoplakia cases 
(Fonseca‐Silva et al., 2016), the loss of the heterozygosity of the p53 allele has been 
reported. In oral cancers, a rearrangement in the 5' region and in the coding of the p53 
gene has been observed as well (Patnaik et al., 1999).  
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Figure 2.6 Possible oncogenes and tumor suppressor genes involved in oral cancer 
as the tumor progress from normal to squamous cell carcinoma (Knopf et al., 2015). 
2.6.3 Genomic instability 
Genomic instability displays the predilection of the genome to achieve multiple 
alterations, for instance microsatellite instability (MSI) and loss of heterozygosity (LOH) 
in repetitive sequences, which may contribute to TSG inactivation (Ram et al., 2011). 
Frequent LOH on chromosomes 3p, 9p, 13q and 17p has been reported as an early event 
in OSCC (Graveland et al., 2011) and related with the transformation of pre-malignant 




Figure 2.7 Presentation of phenotypical progression and accumulated molecular 
alterations in head and neck carcinogenesis. EGFR=epidermal growth factor receptor. 
PTEN=phosphatase and tensin homologue (Feldman et al., 2016). 
2.6.4 Immortalization by telomerase activity  
As the loss of telomeres occurs during cell divisions, the chromosomal ends are 
no longer secured, leading to the fusion of chromosomes and karyotypic irregularities 
which ultimately result in cell death. The ribonucleoprotein enzyme telomerase is inactive 
in normal cells but active in most (90%) of the human cancers (Sinevici and O’sullivan, 
2016). Several studies have reported high telomerase activity in oral cancers such as 
OSCC (Benhamou et al., 2016; Boscolo-Rizzo et al., 2016; Li et al., 2011; Miyazaki et 
al., 2015; Samadi et al., 2018; Zhao et al., 2015). 
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2.6.5 Angiogenesis  
As the tumour grows, it will eventually reach a size where it requires additional 
vasculature to sustain continued growth. To achieve this, the tumour cells excrete certain 
proteins to stimulate blood vessel growth into and around the tumour, a process called 
angiogenesis (Hasina and Lingen, 2001). Vascular endothelial growth factor (VEGF) 
affects the endothelial cells that lines the blood vessels in a number of ways; (Bateman et 
al.) It can cause them to proliferate by activating the extracellular kinases and mitogen-
activated protein (MAP) kinase signal transduction pathway (2) It can induce proteins that 
breakdown the basement membrane to allow the endothelial cells to migrate and invade. 
These proteins include matrix metalloproteinases (MMPs), urokinase plasminogen 
activator (uPA) and its receptor uPAR as well as tissue plasminogen activator (Benowitz 
et al.) It makes vessels more permeable allowing molecules and fluids to leak out. When 
MMP is secreted into the extracellular space, it degrades the extracellular matrix to allow 
proangiogenic factors to reach the vasculature. With the extracellular matrix degraded, 
pro-angiogenic factors including VEGF can reach receptors on the endothelial cells of the 
blood vessels surrounding the tumour. Thus, stimulating the angiogenic signal in the 
vessel. VEGF also helps the new endothelial cells survive by upregulating inhibitors of 
apoptosis. VEGF also activates the endothelial cells to express the proteins necessary to 
allow the new blood vessels to form. The end result is the growth of new blood vessels 
into the tumour. Because of this growth, additional nourishment can be delivered to the 
tumour. This angiogenesis facilitates further growth of tumour.    
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Figure 2.8 The angiogenic cascade. During the process of angiogenesis, stable 
vessels (a) undergo a vascular permeability increase, which allows extravasation of 
plasma proteins (b). Degradation of the ECM by MMPs relieves pericyte-EC contacts 
and liberates ECM-sequestered growth factors (c). ECs then proliferate and migrate to 
their final destination (d) and assemble as lumen-bearing cords (e). ECM, extracellular 
matrix; MMPs, matrix metalloproteases; EC, endothelial cell (Bryan and d’Amore, 
2007).  
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2.7 Clinical features of oral cancer 
2.7.1 Symptoms of oral cancer  
Pain is a usual symptom in patients of oral carcinoma which accounts for 30-40% 
of their chief complaints (Cuffari et al., 2006). Although, pain is a chief symptom, it 
usually happens only when a lesion has reached a considerable size. Since, the early 
carcinomas are asymptomatic, they often go unnoticed (Scully and Bagan, 2009). Other 
symptoms include bleeding, breathing problems, dysphagia, ear pain, paresthesia, 
problems using prosthesis, speech difficulty, teeth mobility and trismus (Haya‐Fernández 
et al., 2004). 
2.7.2 Clinical presentation 
2.7.2(a) Initial stages 
The clinical presentation of an early lesion is usually an erythroleukoplastic lesion 
(Mashberg et al., 1989). It is well demarcated and contains red or red and white patches 
with a slight roughness (Figure). On palpation, the elasticity of the soft tissue alters to a 
harder sensation. The lesion is often asymptomatic, however there might be some 
discomfort (Bagan et al., 2010). 
 
